摘要
目的观察蛭蛇通络胶囊联合西药治疗缺血性脑卒中恢复期气虚血瘀证患者的临床疗效。方法将156例缺血性脑卒中恢复期气虚血瘀证患者随机分为对照组和治疗组各78例。对照组采用基础规范治疗和脑卒中的三级康复治疗方案,治疗组在对照组基础上加用蛭蛇通络胶囊,每次4粒(每粒0.5 g),每日3次,两组患者均用药8周。观察两组患者治疗前后总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)和低密度脂蛋白胆固醇(LDL-C)水平,并在治疗前和治疗后2、4、8周分别进行中医证候积分、美国国立卫生研究院卒中量表(NIHSS)评分和改良Rankin量表评分,并判定临床疗效。结果治疗组临床总有效率为79.22%,对照组为67.11%,治疗组优于对照组(P<0.05)。两组治疗后TC、TG、LDL-C水平均较治疗前降低,HDL-C水平升高(P<0.05或P<0.01)。治疗组治疗后LDL-C水平降低和HDL-C水平升高较对照组显著(P<0.05)。与治疗前比较,治疗组在治疗后4、8周中医证候积分、NIHSS评分和改良Rankin量表评分均降低(P<0.05或P<0.01);对照组治疗后8周中医证候积分、NIHSS评分和改良Rankin量表评分均降低(P<0.05)。与对照组治疗后同时间比较,治疗组治疗后4周和8周中医证候积分、NIHSS评分均降低(P<0.05)。治疗组治疗后8周改良Rankin量表评分较对照组同时间降低更明显(P<0.05)。结论蛭蛇通络胶囊联合西药治疗缺血性脑卒中恢复期气虚血瘀证患者可有效降低血脂,改善临床症状,恢复神经功能和日常生活能力。
Objective treating ischemic stroke conv To observe the clinical effect of Zhishe Tongluo Capsule combined alescence phase patients of Qi deficiency and blood stasis syndrome. with west medicine Methods Totally 156 ischemic stroke convalescence phase patients of Qi deficiency and blood stasis syndrome were randomly divided into control group and treatment group, each of 78 cases. Control group were given basic standard treatment and third- level rehabilitation program. Treatment group were added oral Zhishe Tongluo Capsule, 4 capsules each time （0. 5 g each capsules）, 3 times a day. Both groups were treated for 8 weeks. Observe blood lipid including total cholesterol （TC）, triglyceride （TG）, high density lipoprotein cholesterol （HDL-C） and low density lipopro tein cholesterol （LDL-C） level in both groups before and after treatment. Evaluate therapeutic effect adopting Chinese medicine syn- drome scores, National Institute of Health stroke scale （NIHSS） and Modified Rankin Scale before treatment and 2, 4, 8 weeks after treatment. Results Total effective rate in treatment group was 79. 22%, 67. 11% in control group （ P 〈 0.05 ）. TC, TG and LDL-C in both groups were decreased after treatment, while HDL-C increased （ P 〈 0.05 or P 〈 0. 01 ）. The decrease of LDL-C and increase of HDL-C in treatment group was significant compared with that in control group after treatment （ P 〈 0. 05 ）. Scores of Chinese medicine syndrome, NIHSS and Modified Rankin Scale in treatment group were decreased after 4 and 8 weeks treatment （ P 〈 0.05 or P 〈 0. 01 ）. Scores in control group were decreased after 8 weeks treatment （P 〈 0. 05 ）. Scores of Chinese medicine syndrome and NIHSS in treatment group were lower than those in control group after 4 and 8 weeks treatment （ P 〈 0. 05 ）. Scores of Modified Rankin Scale in treatment group decreased more significantly than those in control group after 8 weeks treatment （P 〈 0. 05 ）. Conclusion Zhishe Tongluo Capsule combined
出处
《中医杂志》
CSCD
北大核心
2015年第19期1659-1662,共4页
Journal of Traditional Chinese Medicine
基金
国家自然科学基金(30973830)
2012年国家临床重点专科(中医专业)建设项目
陕西省二○一三年科技统筹创新工程(2013KTCQ03-05)
